Mark C. McKenna - May 20, 2022 Form 4 Insider Report for Prometheus Biosciences, Inc. (RXDX)

Role
Chairman, President & CEO, Director
Signature
Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
Stock symbol
RXDX
Transactions as of
May 20, 2022
Transactions value $
$0
Form type
4
Date filed
5/20/2022, 07:11 PM
Previous filing
Dec 3, 2021
Next filing
Dec 13, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Option (Right to Buy) Award $0 +247K $0.00 247K May 20, 2022 Common Stock 247K $29.56 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest in full on the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.